Business Wire

Art + Cultural and Creative Products Giving New Life to Cultural Relics

17.11.2022 12:56:00 EET | Business Wire | Press release

Share

An international themed achievement exhibition of “THE BIG DRAW ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was held at the Sanxingdui Museum on November 16, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116006124/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

“THE BIG DRAW, UK Arts Charity launched ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was co-hosted by Sichuan Provincial Department of Culture and Tourism, Deyang Municipal People’s Government, Sichuan Provincial Cultural Heritage Administration, and Hong Kong Trade Development Council; co-organised by Sichuan Publicity Information Center for Culture and Tourism, Sichuan Provincial Academy of Arts, and Management Committee of Sanxingdui Museum; supported by Sichuan Provincial Cultural Relics and Archaeology Research Institute and Deyang Municipal Bureau of Culture, Radio, TV and Tourism. Since the event was launched in June 2022, it has attracted 33 renowned artists from 22 countries and regions and nearly 2,000 participants from over 80 schools and universities.

Yan Sashuang, Vice Director General of Sichuan Provincial Department of Culture and Tourism, presided over the event of the themed achievement exhibition. Dai Yunkang, Vice Director General of the Publicity Department of the CPC Sichuan Provincial Committee, addressed the event. Dai pointed out that Sichuan is a renowned tourist destination in China for its unique Ba-Shu culture and ancient Shu culture. This event attracted artists, art lovers and children worldwide to portray Sanxingdui in their eyes, breathing new life into cultural relics.

He Ping, vice mayor of Deyang Municipal People’s Government, said this event significantly promoted the creative inheritance of Sanxingdui culture and opened a new chapter in the innovative application of cooperation outcomes.

Jacky Chung, Director of the Chinese mainland of Hong Kong Trade Development Council, pointed out that the event is another proof of the in-depth cooperation between Sichuan’s museums and cultural institutions and Hong Kong-funded enterprises.

Kam Panesar, The Big Draw Brand Ambassador in China said, “The UK's expertise in museum and galleries culture and creative tourism is world class. Together with Sichuan Provisional Bureau for Culture and Tourism is an ingrained part of the UK's Arts & Cultural knowledge to implement people centred cultural and artistic festivals in both the UK and China.”

Sanxingdui Culture and Tourism Development Co., Ltd. and BRDGS Partners Group signed an agreement on cultural and creative products cooperation at the site.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sichuan Provincial Department Of Culture and Tourism
Lai Cheuk Fay
ylai18200130301@163.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye